DNA Mutation for Alpha Thalassaemia in Blood With History (Form NIBD) at Chughtai Lab

DNA Mutation for Alpha Thalassaemia in Blood With History (Form NIBD) at Chughtai Lab

The DNA Mutation for Alpha Thalassaemia in Blood With History (Form NIBD) is a highly specialized molecular genetic test designed to identify deletions and mutations within the alpha-globin gene cluster on chromosome 16. Alpha thalassemia is one of the most common autosomal recessive single-gene disorders globally, characterized by a reduction or complete absence of alpha-globin chain synthesis. Because normal adult hemoglobin (Hb A) is a tetramer consisting of two alpha and two beta chains, any deficiency in alpha-chain production leads to an excess of beta chains (in adults) or gamma chains (in fetuses), resulting in unstable hemoglobin molecules, hemolysis, and ineffective erythropoiesis. This molecular assay is critical for diagnosing the precise genetic basis of microcytic hypochromic anemia, distinguishing it from iron deficiency anemia, and identifying carriers who may be at risk of passing severe hemoglobinopathies to their offspring.

The alpha-globin gene cluster is located on the short arm of chromosome 16 (16p13.3) and contains two functional alpha-globin genes, HBA1 and HBA2, on each chromosome. Consequently, a normal diploid individual possesses four functional alpha-globin genes, represented genotypically as αα/αα. The clinical severity of alpha thalassemia correlates directly with the number of functional alpha-globin genes that are deleted or mutated. Deletions are the most common cause of alpha thalassemia, arising from unequal homologous recombination during meiosis. However, non-deletional mutations, such as point mutations or small insertions/deletions within the HBA1 or HBA2 genes, also occur and can lead to severe clinical phenotypes. The DNA Mutation for Alpha Thalassaemia in Blood With History (Form NIBD) at Chughtai Lab utilizes advanced molecular techniques, such as Polymerase Chain Reaction (PCR) and Multiplex Ligation-dependent Probe Amplification (MLPA), to detect these genetic variations with high sensitivity and specificity.

A unique and critical component of this test is the integration of the Form NIBD (National Institute of Blood Diseases) clinical history form. Genetic testing for hemoglobinopathies cannot be interpreted in isolation. The clinical presentation, complete blood count (CBC) parameters, hemoglobin electrophoresis or High-Performance Liquid Chromatography (HPLC) profiles, and family pedigree are essential pieces of the diagnostic puzzle. The Form NIBD serves as a comprehensive clinical document that captures these vital details, allowing the molecular pathologists at Chughtai Lab to perform a highly accurate genotype-phenotype correlation. This ensures that the genetic report is not merely a list of mutations but a clinically actionable diagnostic tool that guides therapeutic decisions, genetic counseling, and prenatal planning.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the accuracy and clinical utility of the DNA Mutation for Alpha Thalassaemia in Blood With History (Form NIBD) test, patients must adhere to the following preparation guidelines:

• Complete the NIBD Form: The patient or referring physician must fully complete the Form NIBD, detailing the clinical history, family history of thalassemia, and previous laboratory findings.
• Provide Previous Reports: It is mandatory to submit copies of the patient’s latest Complete Blood Count (CBC) and Hemoglobin Electrophoresis or HPLC reports along with the sample.
• No Fasting Required: There are no dietary restrictions or fasting requirements for this test. Patients may eat and drink normally prior to sample collection.
• Transfusion History: If the patient has received a blood transfusion recently, this must be clearly documented on the Form NIBD. Ideally, molecular testing should be deferred for 3 to 4 months post-transfusion to avoid contamination with donor DNA, or specific molecular techniques must be employed.
• Medication Documentation: Inform the laboratory staff of any ongoing medications, particularly those affecting hematopoiesis or immunosuppressive therapies.

During the Procedure

The sample collection process is straightforward, safe, and performed by certified phlebotomists at Chughtai Lab:

• Patient Identification: The phlebotomist will verify the patient’s identity using at least two independent identifiers and confirm that the Form NIBD is fully completed.
• Venipuncture: The skin over a suitable vein (usually in the antecubital fossa of the arm) is cleansed with an antiseptic alcohol swab. A sterile, single-use needle is inserted to draw blood.
• Sample Collection: Approximately 3 to 5 mL of whole blood is collected into an EDTA (purple top) tube. EDTA is the preferred anticoagulant as it preserves cellular integrity and prevents DNA degradation.
• Post-Collection Care: The needle is removed, and gentle pressure is applied to the puncture site with a sterile cotton ball to stop any bleeding. A small adhesive bandage is applied.
• Sample Handling: The tube is gently inverted 8 to 10 times to ensure thorough mixing of the blood with the anticoagulant. The sample is labeled immediately with the patient’s unique barcode and prepared for transport to the molecular diagnostics laboratory under controlled temperature conditions.

When is a DNA Mutation for Alpha Thalassaemia in Blood With History (Form NIBD) Performed?

Evaluation of Unexplained Microcytic Hypochromic Anemia

Physicians request this test when a patient presents with persistent microcytic hypochromic anemia (characterized by low mean corpuscular volume [MCV] and low mean corpuscular hemoglobin [MCH]) but has normal iron stores (normal serum ferritin, iron, and total iron-binding capacity). When iron deficiency anemia is ruled out and hemoglobin electrophoresis shows normal or low Hb A2 levels, alpha thalassemia trait is highly suspected. This molecular test is performed to confirm the diagnosis, preventing unnecessary and potentially harmful long-term iron supplementation.

Family Screening and Genetic Counseling

Alpha thalassemia is an inherited genetic disorder. If a family member is identified as a carrier or diagnosed with Hemoglobin H disease, other family members—particularly prospective parents—are recommended to undergo this test. Identifying carriers of alpha-globin gene deletions (especially the cis-deletion pattern common in Southeast Asian and Mediterranean populations) is crucial for genetic counseling, helping couples understand their risk of having a child with severe forms of the disease.

Prenatal Diagnosis and Risk Assessment

In cases where both parents are confirmed carriers of alpha-globin gene deletions, there is a significant risk of transmitting severe hemoglobinopathies to their offspring. This test is performed as a preliminary step to characterize the parental mutations precisely. Once the parental genotypes are known, prenatal diagnostic procedures (such as chorionic villus sampling or amniocentesis) can be performed to determine if the fetus has inherited a fatal condition like Hb Bart’s Hydrops Fetalis.

Investigation of Hemoglobin H (Hb H) Disease

Patients presenting with chronic hemolytic anemia, splenomegaly, mild jaundice, and characteristic red blood cell morphology (such as target cells and Heinz bodies) are evaluated for Hemoglobin H disease. While Hb H can sometimes be detected via brilliant cresyl blue staining or HPLC, molecular testing is the gold standard to definitively identify the specific three-gene deletion or non-deletional mutation pattern, allowing for appropriate clinical management and monitoring.

Premarital Screening in High-Risk Populations

In regions with a high prevalence of hemoglobinopathies, such as Pakistan, premarital screening is an essential public health strategy. The DNA Mutation for Alpha Thalassaemia test, accompanied by the detailed Form NIBD, is performed to identify asymptomatic carriers before marriage. This proactive screening empowers couples to make informed reproductive choices and reduces the national burden of severe genetic blood disorders.

What Does a DNA Mutation for Alpha Thalassaemia in Blood With History (Form NIBD) Detect?

This comprehensive molecular assay is capable of detecting a wide spectrum of genetic variations within the HBA1 and HBA2 genes, including:

• Normal Alpha-Globin Genotype: Presence of all four functional alpha-globin genes (αα/αα).
• Single-Gene Deletion (α+ Thalassemia Carrier): Deletion of one alpha-globin gene, typically the -α3.7 deletion.
• Single-Gene Deletion (-α4.2): A less common single-gene deletion variant resulting in a silent carrier state.
• Double-Gene Deletion in Cis (α0 Thalassemia Trait): Deletion of both HBA1 and HBA2 genes on the same chromosome (–SEA, –MED, or –FIL), common in Asian populations.
• Double-Gene Deletion in Trans (α+ Thalassemia Homozygote): Deletion of one gene on each chromosome (-α3.7/-α3.7 or -α4.2/-α4.2), resulting in mild microcytic anemia.
• Triple-Gene Deletion (Hemoglobin H Disease): Deletion of three alpha-globin genes (–/-α), leading to moderate-to-severe hemolytic anemia.
• Four-Gene Deletion (Hb Bart’s Hydrops Fetalis): Deletion of all four alpha-globin genes (–/–), which is incompatible with extrauterine life.
• Hemoglobin Constant Spring (Hb CS): A common non-deletional mutation (HBA2:c.427T>C) producing an unstable, elongated alpha chain.
• Hemoglobin Quong Sze (Hb QS): A non-deletional missense mutation (HBA2:c.377T>C) causing highly unstable alpha-globin.
• Hemoglobin Icaria: A non-deletional stop-codon mutation resulting in an elongated alpha-globin variant.
• Hemoglobin Koya Dora: Another non-deletional variant characterized by a terminal codon mutation.
• Initiation Codon Mutations: Point mutations in the start codon (ATG) of the HBA1 or HBA2 genes, preventing translation.
• Polyadenylation Signal Mutations: Mutations in the AATAAA sequence that impair mRNA processing and stability.
• Donor Splice Site Mutations: Mutations at exon-intron junctions that interfere with normal pre-mRNA splicing.
• Acceptor Splice Site Mutations: Splicing defects leading to aberrant transcripts and reduced alpha-chain synthesis.
• Frameshift Mutations: Insertions or deletions of nucleotides that alter the reading frame, producing non-functional truncated proteins.
• Nonsense Mutations: Premature stop codons resulting in incomplete, rapidly degraded alpha-globin chains.
• Missense Mutations: Single nucleotide substitutions that alter amino acid sequences, affecting hemoglobin stability or oxygen affinity.
• Alpha-Globin Gene Triplication (ααα/αα): An excess of alpha-globin genes, which can exacerbate the clinical severity of co-inherited beta thalassemia.
• Alpha-Globin Gene Quadruplication: Rare copy number variations resulting in five or more functional alpha genes.
• Promoter Region Mutations: Variations in the promoter sequence that reduce transcription efficiency of HBA1 or HBA2.
• Co-inherited Beta-Thalassemia Mutations: Genetic interactions where alpha-globin mutations co-exist with beta-globin defects.
• Co-inherited Sickle Cell Trait: Interaction of alpha-globin deletions with Hb S, which can modify the clinical presentation of sickle cell disease.
• Unclassified Variants of Uncertain Significance (VUS): Novel or rare nucleotide changes within the alpha-globin locus requiring further clinical correlation.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we understand the anxiety and clinical urgency associated with genetic testing. Because the DNA Mutation for Alpha Thalassaemia in Blood With History (Form NIBD) involves complex molecular techniques, including DNA extraction, PCR amplification, and fragment analysis or sequencing, the standard turnaround time is typically 10 to 14 working days. Once the analysis is completed and verified by our consultant molecular pathologists, reports are uploaded immediately to our secure digital database. Patients and referring physicians can access reports online through the Chughtai Lab official website, our dedicated mobile application, or via automated WhatsApp alerts. Physical copies can also be collected from any of our convenient diagnostic centers nationwide.

DNA Mutation for Alpha Thalassaemia in Blood With History (Form NIBD) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Alpha-Globin Gene Copy Number	Four functional genes (αα/αα)	1, 2, or 3 gene deletions; gene triplications (ααα/)
Deletional Mutations	No large deletions detected	Presence of -α3.7, -α4.2, –SEA, –MED, –FIL deletions
Non-Deletional Mutations	Wild-type sequence in HBA1 and HBA2	Hb Constant Spring, Hb Quong Sze, point mutations
Red Blood Cell Indices (MCV/MCH)	Normal MCV (≥80 fL), Normal MCH (≥27 pg)	Microcytosis (low MCV), Hypochromia (low MCH)
Hemoglobin Electrophoresis Correlation	Normal Hb A (>95%), Hb A2 (2.5-3.5%), Hb F (<1%)	Presence of Hb H, Hb Bart’s, or altered Hb A2 levels
Clinical History (Form NIBD)	No family history of unexplained severe anemia	Positive family history, prior transfusion dependence
Genotype-Phenotype Correlation	Asymptomatic, normal hematological profile	Silent carrier, alpha thal trait, Hb H disease, Hydrops Fetalis

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for DNA Mutation for Alpha Thalassaemia in Blood With History (Form NIBD)?

• Experienced Healthcare Professionals: Our molecular diagnostics division is led by highly qualified consultant pathologists and geneticists with extensive experience in hemoglobinopathies.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate care throughout the testing process.
• Quality Diagnostic Services: Chughtai Lab adheres to strict international quality control standards, ensuring the highest accuracy in molecular testing.
• Professional Reporting: Our reports provide comprehensive genotype-phenotype correlations, making complex genetic data easy for clinicians to interpret.
• Modern Diagnostic Approach: We utilize state-of-the-art PCR, MLPA, and sequencing technologies to detect both common and rare alpha-globin mutations.
• Comfortable Environment: Our nationwide collection centers offer a clean, professional, and welcoming environment for sample collection.
• Convenient Location: With hundreds of locations across Pakistan, finding a Chughtai Lab center near you is simple and convenient.
• Commitment to Accurate Diagnosis: We integrate detailed clinical histories via the Form NIBD to ensure that every result is clinically validated and reliable.